RGEN vs SYRE
Repligen vs Spyre Therapeutics, Inc. — AI-powered side-by-side comparison
VS
SYRE
Spyre Therapeutics, Inc.
67
Buy
| Metric | RGEN | SYRE |
|---|
| AI Score |
60
|
67
|
| Price |
$180.00
|
$94.72
|
| P/E Ratio |
245.53×
|
-55.06×
|
| ROE |
2.3%
|
-21.7%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
51.1%
|
0.0%
|
| Debt / Equity |
0.33×
|
0.00×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
83.2
|
59.9
|
| Beta |
1.012
|
3.026
|
| Expected Upside |
+0.0%
|
—
|
AI Committee View
Current Innellis committee reasoning for RGEN versus SYRE.
SYRE leads by 7 points.
SYRE scores 67/100 (Buy) versus RGEN at 60/100 (Buy).
RGEN Committee View
50% agreement
6 analysts
The committee is genuinely divided. Growth Analyst sees a compelling case — 4 consecutive earnings beats -- consistent execution. Value Analyst remains cautious — p/e of 227.0 is expensive by classic value standards. This disagreement is itself the signal — the setup is not clean in either direction.
Bull Case
- 4 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
Bear Case
- P/E of 227.0 is expensive by classic value standards — Value
- Price-to-book of 4.4x prices in significant intangible value — Value
- ROE of only 2.0% -- cheap may mean cheap for a reason — Value
SYRE Committee View
67% agreement
6 analysts
The committee is split. Analysts see this stock differently enough that the current rating reflects genuine uncertainty, not a weak signal.
Bull Case
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- Price structure making higher highs and higher lows — Technical
- Trend and market structure agree -- coherent bullish picture — Technical
Bear Case
- ROE of only -24.3% -- cheap may mean cheap for a reason — Value
- MACD histogram negative -- bearish momentum — Technical
- Weekly RSI at 81 -- overbought on the larger timeframe too — Technical